Vertex Pharmaceuticals Third Quarter 2026 Earnings Call - CRINETICS PHARMACEUTICALS INC

Explicit Guidance:

• FY2026 Total Revenue: Revised upward to $12.5–12.8 billion (from $13.1–13.2B); includes ~$40–50M contribution from Krenetics.
• FY2026 Gross Margin: Expected to remain slightly below 86%.
• FY2026 Operating Expenses: Revised non-GAAP estimate to approx. $6.0 billion (up from $5.65–5.75B); driven by ~$250M integration and operating costs for Krenetics.
• FY2026 Non-Operating Costs: Projected at approx. $105 million (higher interest expense related to Krenetics financing) and ~$60M lower interest income due to reduced cash balances.
• FY2026 Effective Tax Rate: Expected between 19.5% and 20.5%.
• FX Impact: Expecting a full-year benefit of roughly 150 basis points.
• Revenue Diversification: Targeting >$500M combined non-CF revenue from Casgevi, Jernavix, and Palsonify in 2026.
• FY2026 Prescriptions (Jernavix): Expects >3x the number of prescriptions in 2026 vs. 2025.
• Palsonify Revenue (YTD 2027): Forecast approx. $60 million for the first three quarters.

Business-Segment Outlook:

• Cystic Fibrosis (CF): Global revenue growth to be driven by label expansions (rare mutations), younger age groups (global submissions initiated for ages 2–5), and geographic penetration. OliVtrac (Eliftrac) treated >18,000 patients globally; sales surpassed $1B YTD in the U.S.
• Heme (Casgevi): Expected to contribute to >$500M non-CF revenue in 2026; infusions are expected to continue growing into 2027, with strong visibility into infusion timing despite Q4 seasonality.
• Pain (Jernavix): PSP (patient support program) extended into 2027; gross-to-net expected to stabilize at 50–60% by mid-2027 upon sunset. Revenue expected to grow commensurately with gross-to-net normalization. Targeting a multi-billion dollar franchise.
• Rare Endocrinology (Palsonify): U.S. launch progressing with >40% brand share; focus on expanding repeat HCP writers. International launches planned following U.S. performance.
• Renal (Povitacicept/POVI): Launch readiness "100%" with PDUFA date Nov 30. Ambition to launch globally; KSA filing secured with breakthrough status (7,000 patient opportunity). Two-year EGFR data planned for global filings (FDA may accept 1-year; other regulators require 2-year).
• Renal (Anaxiplin/AMKD): Full enrollment completed in pivotal Amplitude trial; interim analysis results expected early 2027. Success metric defined as statistically significant GFR improvement (agreed with FDA for accelerated approval).
• Renal (VX407/ADPKD): GLO Phase 2 study readout expected next year.
• T1D (VX017): Phase 1-2 dosing underway; goal to demonstrate proof-of-concept and scale manufacturing to move to pivotal development in 2027.
• Pain (VX548/VX993): Enrolling in Phase 3 trials for painful diabetic peripheral neuropathy (DPN); enrollment completion expected by year-end, with data readout by mid-2027.
• Myasthenia Gravis (VX065): Proof-of-concept data for Aetna study expected first half of 2027.
• Myotonic Dystrophy (VX670): Interim results from Phase I-II Galileo trial expected before year-end.

Market and Competitive Outlook:

• Competitive Landscape: POVI positioned for "best-in-class" potential via efficacy, tolerability, and patient-centric auto-injector (low volume, q4w dosing).
• Market Share: Palsonify holds leading brand share (>40%) in acromegaly initiation/switch settings; Casgevi initiated >750 patients worldwide with >100 initiations per quarter for four consecutive quarters.
• Payer Access: Secured broad Medicare Part D access for Jernavix (July); ~82% managed lives covered for Jernavix.
• Patient Demand: 1.6M+ patients treated with Jernavix; 96% of IGAN patients prefer auto-injector over syringe; 80% prefer q4w dosing over weekly.

Macro / Industry Outlook:

• Regulatory (PDUFA): High confidence in Nov 30th PDUFA approval for POVI in IGAN.
• Regulatory (Global): Strategy involves filing for two-year EGFR data for global launches, though FDA is comfortable with one-year GFR data for accelerated approval.
• Manufacturing: Confident in continuous manufacturing process for biologics; FDA fully engaged with CMC package; no concerns regarding supply readiness.
• FX: Favorable foreign exchange impact anticipated for full year 2026.

Strategic Initiatives:

• Krenetics Acquisition: Integration underway; contributing ~$10M in Q3 revenue; full-year revenue impact ~$40–50M.
• Leadership Transition: Charlie Wagner (CFO) transitioning to COO solely; Jonathan Poole (SVP Finance) named successor as CFO effective Jan 1, 2027.
• Pipeline Advancement: Selecting VX017 as lead T1D program to double eligible patient pool (allogeneic, all blood types) vs. VX011.
• Next-Gen CF: Waiting for complete data on NG 3.0 family (VX828, VX581, VX272) before selecting candidate for pivotal development; NG 4.0 molecules in late preclinical.
• Acromegaly (Palsonify): First once-daily oral SST2 selective agonist; targeting switch and naive patients.
• Acromegaly Expansion: Phase 3 pivotal trial for Atumelanant in congenital adrenal hyperplasia (CAH) enrolling; target completion of enrollment Q1 2027.
• Pivotal Development: Goal to rapidly advance pediatric Atumelanant into pivotal development following regulatory interactions.

Risks and Headwinds to Outlook:

• Seasonality: Q4 infusion timing for Casgevi subject to patient choice and seasonality; management advises focusing on annual performance.
• Regulatory Uncertainty: Potential for citizen petitions (e.g., regarding POVI monitoring) or differing global regulatory expectations (e.g., 2-year data requirements).
• Clinical Execution: Success of Anaxiplin dependent on GFR separation at 1-year interim; success of DPN trials dependent on beating placebo.
• Financial Impact: One-time impacts from PSP sunset (net revenue reset) and Krenetics acquisition costs (interest, integration) affecting near-term margins and OpEx.
• Pricing/Reimbursement: Ongoing need to secure broad payer access for Jernavix to convert uncontracted prescriptions to contracted/rebated pricing.

Management Tone on the Future:

• Confidence Level: High degree of certainty in revenue guidance; "incredibly excited" about POVI launch; "excellent results" for pain franchise and rare endocrinology.
• Strategic Shift: Moving from CF-only to five-disease-area company; emphasizing "acceleration" of commercial and clinical programs.
• Commitment: Continued investment in late-stage pipeline and commercial infrastructure; PSP extension signals commitment to long-term franchise growth over short-term margin preservation.
• Tone: "Optimistic," "Confident," "Excellence in execution."

Miscellaneous:

• M&A Financing: $4.5B term loans raised for Krenetics acquisition, bearing approx. 4.8% interest.
• Capital Allocation: Priority remains innovation (internal/external); share repurchases continue ($120M deployed in Q3).
• Clinical Data: Rainier Phase 3 interim data for POVI published in NEJM; Amplified data for Anaxiplin shows robust proteinuria reduction (42.7% UACR reduction in modest proteinuria cohort).